62 results
Page 2 of 4
DEFA14A
fgzrp64f3 c0r
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
3f7lb02u9bl kb9e
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
zc67j3moai5 u8ayp2j
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
EX-1.1
7c4la5l ctr
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
424B5
h9j94qq
11 Sep 20
Prospectus supplement for primary offering
4:44pm
424B5
t45spcquysp03xk
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
8st6ys85c49ti
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
0i0r 1q90t
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
b46h3dpxxtscn7j
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
rt2pdjuu cligvh8v71
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-1.1
2y9ii
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
424B5
ee4uippj2tl1wki6ahe
8 Jan 20
Prospectus supplement for primary offering
5:06pm